

リウマチ内科グループ 英語論文の業績 2021 年

- 1) Nishiyama H, Tajiri T, Yamabe T, Yasukawa T, Takeda N, Fukumitsu K, Fukuda S, Kanemitsu Y, Uemura T, Ohkubo H, Takemura M, Maeno K, Ito Y, Oguri T, Naniwa T, Niimi A. **Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody.** Intern Med. **60(22)**:3631-3634, 2021.
- 2) Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, Kuwana M. **The Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.** Arthritis Rheumatol. **73(4)**:677-686, 2021.
- 3) Tamechika SY, Isogai S, Maeda S, Naniwa T, Niimi A. **Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab.** Case Rep Rheumatol. **29**;2021:5561762, 2021.
- 4) Naniwa T, Uehara K, Yamabe T, Ohmura SI. **Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still's disease with a previous successful tocilizumab treatment.** Mod Rheumatol Case Rep. **5(2)**:360-364, 2021.
- 5) Ohmura SI, Yamabe T, Naniwa T. **Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.** Mod Rheumatol Case Rep. **5(1)**:76-81, 2021.